Aurobindo Pharma receives warning letter from SEBI

27 Jun 2022 , 03:14 PM

Aurobindo Pharma has received a warning letter from Securities Exchange Board of India (SEBI) on 24 June 2022. The letter is in regards to certain disclosures made by the Company on the ongoing USFDA audit of Companys Unit-1 and observations made by the USFDA between the period 2019 to 2022. The SEBI warning letter observes that the Company had disclosed very limited and restricted information and that the Company did not disclose the detailed reasons and also did not consider-the observations of USFDA as serious. The Company is advised to ensure compliance with all applicable provisions of SEBI Regulations and to place this warning letter before its Board of Directors in ensuing Board Meeting.Powered by Capital Market – Live News